As per the agreement, Alexion will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of LogicBio for $2.07 per share, a rare 660% premium on LogicBio’s share price.

His experience also includes M&A and corporate development at LogicBio Therapeutics ... creating a robust pipeline targeting CNS, neuromuscular and eye diseases. Headquartered in Paris, France ...